,Response,Percentage of R&D investments
0,Pre-human/pre-clinical,16.4%
1,Clinical trials,49.2%
2,Phase I*,9.7%
3,Phase II*,10.6%
4,Phase III*,28.9%
5,Approval,3.3%
6,Pharmacovigiliance (Phase IV),11.6%
7,Uncategorized,19.4%
